Aeris CE marks lung sealant system for emphysema

21 Sep 2010

• By Madeleine Armstrong

Aeris Therapeutics has CE marked its AeriSeal system for sale in Europe. The lung sealant device, which is intended for patients with emphysema, is a safer method of reducing lung volume than surgery, the company believes. During the surgical procedure, patients have diseased portions of their lung removed using a stapling device or laser ablation, in order to improve the function of the healthier areas of their lungs. Aeris' product uses a bronchoscope to identify the most damaged areas, before delivering AeriSeal foam sealant via a catheter. The foam polymerises and seals the diseased regions; over time these regions collapse, thereby reducing lung volume. The Woburn, Massachusetts-based firm estimates that the EU emphysema treatment market is worth about $7bn.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Final Chance To Have Your Say: Take Our Reader Survey This Week

17 Sep 2024

• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

04 Sep 2024

• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

22 Aug 2024

• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

09 Jul 2024

• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

Panel: FDA’s Home Healthcare Initiative Holds Promise, But Challenges Remain

06 Jun 2025

• By Elizabeth Orr

During a recent FDLI panel, experts discussed the FDA's Home Healthcare initiative, highlighting its potential benefits and challenges. Key issues include usability testing, reimbursement, labeling for home use, and the need for innovation while ensuring patient safety.